WMIC 2022

Preclinical data demonstrating hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801 can be reproducibly synthesized and is suitable for human use.

WMIC 2022

Preclinical data demonstrating that our hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801, can detect activated macrophages and microglia with high sensitivity and specificity in an experimental autoimmune encephalomyelitis (EAE) murine model of multiple sclerosis (MS).

AAIC 2022

Novel hydroxyl dendrimer-based PET tracer [18F]OP-801 detects early-stage neuroinflammation in 5xFAD mouse model with higher sensitivity than TSPO-PET

NF Conference 2022

Hydroxyl Dendrimer Therapeutics Reduce Toxicity in Targeted Delivery to Plexiform Neurofibroma

ARVO 2022

Safety and Tolerability of a Single Subcutaneous Dose of Anti-Angiogenesis Drug to Treat Neovascular Age-related Macular Degeneration (wet AMD) and Diabetic Macular Edema (DME)

WMIC 2021

Development of a novel hydroxyl dendrimer SPECT tracer, 111In-D6-B483, for selective imaging of brain tumors

WMIC 2021

Development of 18F-OP-801: A Novel Hydroxyl Dendrimer PET Tracer for Imaging Maladaptive Inflammation in the Whole Body and Brain

ARVO 2021

Single Subcutaneous (or Oral) Dose of Anti-Angiogenesis Drug Safely Suppresses Choroidal Neovascularization Comparable to Intravitreal Aflibercept

AASLD 2020

Hepatocyte Targeted Therapy to Enhance Efficacy and Safety of Drugs for Liver Diseases